Activity of the inflammatory process in different types of unstable atherosclerotic plaques

Yu I Ragino1, A M Chernyavski, Ya V Polonskaya

  • 1Institute of Therapy, Siberian Division of the Russian Academy of Medical Sciences, Novosibirsk, Russia. ragino@mail.ru

Insights

Researchers identified key inflammatory biomarkers in unstable coronary plaques. Elevated levels of specific interleukins (IL) and monocyte chemotactic protein-1 were found in both lipid and inflammatory erosive plaque types.

Area of Science:

  • Cardiovascular biology
  • Immunology
  • Pathology

Background:

  • Unstable plaques in coronary atherosclerosis pose a significant risk.
  • Different plaque types (lipid, inflammatory erosive, degenerative necrotic) exhibit distinct characteristics.
  • Understanding the inflammatory basis of plaque instability is crucial for risk stratification.

Purpose of the Study:

  • To identify and study inflammatory biomarkers and chemoattractants in different types of unstable coronary plaques.
  • To compare the inflammatory profiles of lipid, inflammatory erosive, and degenerative necrotic plaque types.
  • To elucidate the role of inflammation in the development of various unstable plaque morphologies.

Main Methods:

  • Analysis of inflammatory biomarkers and chemoattractants in male patients with coronary atherosclerosis.
  • Characterization of unstable plaque types: lipid, inflammatory erosive, and degenerative necrotic.
  • Quantitative measurement of interleukin-1 beta (IL-1β), IL-6, IL-8, IL-18, and monocyte chemotactic protein-1 (MCP-1) concentrations.

Main Results:

  • Elevated concentrations of IL-1β, IL-6, IL-8, IL-18, and MCP-1 were observed in both inflammatory erosive and lipid plaque types.
  • These inflammatory markers were significantly higher in lipid and inflammatory erosive plaques compared to the degenerative necrotic type.
  • The findings indicate a shared inflammatory pathway contributing to the development of different unstable plaque subtypes.

Conclusions:

  • Intensification of the inflammatory process is pivotal in the development of not only inflammatory and destructive but also lipid types of unstable atherosclerotic plaques.
  • Specific inflammatory biomarkers are key indicators differentiating unstable plaque subtypes.
  • Targeting inflammatory pathways may offer therapeutic strategies for managing diverse forms of coronary plaque instability.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Inflammation01:38

Inflammation

Overview
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...